Artivion, Inc.
Health
Performance
5.2
Risk
Sell
Buy
Curious about the Scores? Learn more.

Artivion, Inc. stock rating and score history

All changes in ratings, performance and outlook tracked over time.

24.01.2026
Fragile setup. Still failing to meet the key marks today.
13.01.2026
Still winning, but momentum’s cooling a bit.
04.01.2026
Risk creeping up. Stability not bulletproof anymore.
01.01.2026
Pulse detected. Still fragile, but stabilizing.
AORT
Artivion, Inc.
40.40
+0.82%
5.2
Sell
Buy
Artivion, Inc.

Artivion, Inc. stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Artivion, Inc. do? Business model and key facts

Get the full picture of Artivion, Inc.: what it builds, where it operates, and how it makes money.

Artivion, Inc. Profile

Sector: Healthcare

Industry: Medical - Devices

Employees (FY): 1600

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.

shop
Company facts
James Patrick Mackin
CEO
1600
Employees worldwide
shop
Performance
29.3%
Last 12 months
64.02%
Last 5 years
shop
Growth
$388,54M
Revenue year
$-13.359.000
Net income
shop
Valuation
$1,90B
Market Cap
-89.19
Price/Earnings Ratio

Stocks related to Artivion, Inc.

Selected based on industry alignment and relative market positioning.

UFPT
UFP Technologies, Inc.
255.72
+0.17%
6.1
Sell
Buy
UFP Technologies, Inc.
ESTA
Establishment Labs Holdings Inc.
69.57
+0.64%
8.0
Sell
Buy
Establishment Labs Holdings Inc.
INSP
Inspire Medical Systems, Inc.
67.78
-0.67%
8.7
Sell
Buy
Inspire Medical Systems, Inc.
AXGN
AxoGen, Inc.
35.21
+2.89%
6.7
Sell
Buy
AxoGen, Inc.
PRCT
PROCEPT BioRobotics Corporation
28.31
-2.14%
7.0
Sell
Buy
PROCEPT BioRobotics Corporation

Artivion, Inc. fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.